Abstract: Objective To analyze the clinical efficacy of Jianpi Runzao Tongluo Decoction in treating primary Sjogren’s syndrome with spleen deficiency and collateral obstruction. Methods The clinical data of 100 patients with primary Sjogren’s syndrome of spleen-deficiency and collateral obstruction type were selected from January 2019 to October 2020 for retrospective analysis, and they were divided into the observation group (50 cases were treated with Jianpi Tunzao Tongluo Decoction) and the control group (50 cases were treated with conventional western medicine according to different treatment methods. The clinical efficacy of the two groups and the differences in TCM syndrome scores before and after treatment and the disease activity index were compared, and the differences in the incidence of adverse reactions during the treatment of the two groups were counted. Results The observation group was significantly higher than that of the control group (P<0.05); the improvement of the TCM syndrome score and disease activity index of the observation group before and after treatment was significantly higher than that of the control group (P<0.05); adverse reactions occurred during the treatment of the observation group The rate was significantly lower than that of the control group (P<0.05). Conclusion Compared with conventional western medicine treatment, Jianpi Runzao Tongluo Decoction has higher efficacy and safety, can effectively improve the clinical symptoms of Sjogren’s syndrome, and is worthy of popularization.

Key words: Jianpi Runzao Tongluo Decoction, Primary Sjogren's syndrome, Clinical efficacy